A robust high-content imaging approach for probing the mechanism of action and phenotypic outcomes of cell-cycle modulators

Molecular Cancer Therapeutics

Volumn 10, Issue 2, 2011, Pages 242-254

  Sutherland, Jeffrey J ^a   Low, Jonathan ^a   Blosser, Wayne ^a   Dowless, Michele ^a   Engler, Thomas A ^a   Stancato, Louis F ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (8 CYCLOPENTYL 7 ETHYL 5,6,7,8 TETRAHYDRO 5 METHYL 6 OXO 2 PTERIDINYLAMINO) 3 METHOXY N (1 METHYL 4 PIPERIDINYL)BENZAMIDE; 4 [[9 CHLORO 7 (2,6 DIFLUOROPHENYL) 5H PYRIMIDO[5,4 D][2]BENZAZEPIN 2 YL]AMINO]BENZOIC ACID; 6 ACETYL 8 CYCLOPENTYL 5 METHYL 2 [5 (1 PIPERAZINYL) 2 PYRIDINYLAMINO] 8H PYRIDO[2,3 D]PYRIMIDIN 7 ONE; ACLARUBICIN; AG 024322; AG 12286; AMINOPURVALANOL; AURORA KINASE INHIBITOR; BARASERTIB; BMI 1026; BMS 265246; CYC 116; CYCLIN DEPENDENT KINASE INHIBITOR; DANUSERTIB; DIMETHYL SULFOXIDE; DINACICLIB; ENMD 2076; FLAVOPIRIDOL; GSK 461364; HMN 176; JNJ 7706621; N [5 (5 TERT BUTYL 2 OXAZOLYLMETHYLTHIO) 2 THIAZOLYL]ISONIPECOTAMIDE; NOCODAZOLE; ON 01910; PACLITAXEL; PD 171851; POLO LIKE KINASE INHIBITOR; PROTEIN KINASE INHIBITOR; R 547; TOZASERTIB; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTICLE; CELL CYCLE; CELL CYCLE REGULATION; CELL SCREENING; CLASSIFIER; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE MICROSCOPY; PHENOTYPE; PREVALENCE; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; CELL CYCLE; CELL PROLIFERATION; CELLS; DECISION TREES; DOSE-RESPONSE RELATIONSHIP, DRUG; HCT116 CELLS; HUMANS; MICROSCOPY, FLUORESCENCE; MICROTUBULES; PHENOTYPE; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; REPRODUCIBILITY OF RESULTS;

EID: 79951839895     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-10-0720     Document Type: Article

References (43)

1. Levsky JM, Singer RH. Gene expression and the myth of the average cell. Trends Cell Biol 2003;13:4-6. (Pubitemid 35453889)
2. Jones TR, Carpenter AE, Lamprecht MR, Moffat J, Silver SJ, Grenier JK, et al. Scoring diverse cellular morphologies in image-based screens with iterative feedback and machine learning. Proc Natl Acad Sci U S A 2009;106:1826-31.
3. Tao CY, Hoyt J, Feng Y. A support vector machine classifier for recognizing mitotic subphases using high-content screening data. J Biomol Screen 2007;12:490-6. (Pubitemid 46871833)
4. Conrad C, Erfle H, Warnat P, Daigle N, Lorch T, Ellenberg J, et al. Automatic identification of subcellular phenotypes on human cell arrays. Genome Res 2004;14:1130-6. (Pubitemid 38811549)
5. Low J, Huang S, Blosser W, Dowless M, Burch J, Neubauer B, et al. High-content imaging characterization of cell cycle therapeutics through in vitro and in vivo subpopulation analysis. Mol Cancer Ther 2008;7:2455-63.
6. Yin Z, Zhou X, Bakal C, Li F, Sun Y, Perrimon N, et al. Using iterative cluster merging with improved gap statistics to perform online phenotype discovery in the context of high-throughput RNAi screens. BMC Bioinformatics 2008;9:264.
7. Young DW, Bender A, Hoyt J, McWhinnie E, Chirn GW, Tao CY, et al. Integrating high-content screening and ligand-target prediction to identify mechanism of action. Nat Chem Biol 2008; 4:59-68. (Pubitemid 350273652)
8. Perlman ZE, Slack MD, Feng Y, Mitchison TJ, Wu LF, Altschuler SJ. Multidimensional drug profiling by automated microscopy. Science 2004;306:1194-8. (Pubitemid 39489001)
9. Slack MD, Martinez ED, Wu LF, Altschuler SJ. Characterizing heterogeneous cellular responses to perturbations. Proc Natl Acad Sci U S A 2008;105:19306-11.
10. Loo LH, Lin HJ, Steininger RJ 3rd, Wang Y, Wu LF, Altschuler SJ. An approach for extensibly profiling the molecular states of cellular subpopulations. Nat Methods 2009;6:759-65.
11. Loo LH, Wu LF, Altschuler SJ. Image-based multivariate profiling of drug responses from single cells. Nat Methods 2007;4:445-53. (Pubitemid 46901279)
12. Feng Y, Mitchison TJ, Bender A, Young DW, Tallarico JA. Multiparameter phenotypic profiling: using cellular effects to characterize small-molecule compounds. Nat Rev Drug Discov 2009;8:567-78.
13. Low J, Stancato L, Lee J, Sutherland JJ. Prioritizing hits from phenotypic high-content screens. Curr Opin Drug Discov Devel 2008;11: 338-45. (Pubitemid 351572443)
14. Pommier Y. DNA topoisomerase I inhibitors: chemistry, biology, and interfacial inhibition. Chem Rev 2009;109:2894-902.
15. Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer 2004;4:253-65. (Pubitemid 38525281)
16. Lapenna S, Giordano A. Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov 2009;8:547-66.
17. 2-M transition of human cells. J Biol Chem 2010;285:21849-57.
18. Barr AR, Gergely F. Aurora-A: the maker and breaker of spindle poles. J Cell Sci 2007;120:2987-96. (Pubitemid 47517082)
19. Glover DM, Leibowitz MH, McLean DA, Parry H. Mutations in aurora prevent centrosome separation leading to the formation of monopolar spindles. Cell 1995;81:95-105.
20. Girdler F, Gascoigne KE, Eyers PA, Hartmuth S, Crafter C, Foote KM, et al. Validating Aurora B as an anti-cancer drug target. J Cell Sci 2006;119:3664-75. (Pubitemid 44501870)
21. Lane HA, Nigg EA. Antibody microinjection reveals an essential role for human polo-like kinase 1 (Plk1) in the functional maturation of mitotic centrosomes. J Cell Biol 1996;135:1701-13. (Pubitemid 27036434)
22. Peters U, Cherian J, Kim JH, Kwok BH, Kapoor TM. Probing cell-division phenotype space and Polo-like kinase function using small molecules. Nat Chem Biol 2006;2:618-26. (Pubitemid 44610346)
23. Steegmaier M, Hoffmann M, Baum A, Lenart P, Petronczki M, Krssak M, et al. BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo. Curr Biol 2007;17:316-22. (Pubitemid 46241881)
24. 2-M-phase anticancer drugs in human tumor-derived cell lines. Investigational new drugs 2000;18:139-47.
25. 2 arrest: altered regulation of p34cdc2/cyclin B. Cancer research 1992;52:1823-9.
26. Fabian MA, Biggs WH 3rd, Treiber DK, Atteridge CE, Azimioara MD, Benedetti MG, et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nature Biotechnology 2005;23:329-36. (Pubitemid 41094421)
27. Garriga J, Xie H, Obradovic Z, Grana X. Selective control of gene expression by CDK9 in human cells. J Cell Physiol 2010; 222:200-8.
28. Tanaka H, Ohshima N, Ikenoya M, Komori K, Katoh F, Hidaka H. HMN-176, an active metabolite of the synthetic antitumor agent HMN- 214, restores chemosensitivity to multidrug-resistant cells by targeting the transcription factor NF-Y. Cancer research 2003;63:6942-7. (Pubitemid 37322980)
29. Manfredi MG, Ecsedy JA, Meetze KA, Balani SK, Burenkova O, Chen W, et al. Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase. Proc Natl Acad Sci U S A 2007;104:4106-11. (Pubitemid 47181586)
30. Taylor S, Peters JM. Polo and Aurora kinases: lessons derived from chemical biology. Curr Opin Cell Biol 2008;20:77-84.
31. DePinto W, Chu XJ, Yin X, Smith M, Packman K, Goelzer P, et al. In vitro and in vivo activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials. Mol Cancer Ther 2006;5:2644-58.
32. Furuta T, Hayward RL, Meng LH, Takemura H, Aune GJ, Bonner WM, et al. p21CDKN1A allows the repair of replication-mediated DNA double-strand breaks induced by topoisomerase I and is inactivated by the checkpoint kinase inhibitor 7-hydroxystaurosporine. Oncogene 2006;25:2839-49. (Pubitemid 43739234)
33. Kelling J, Sullivan K, Wilson L, Jordan MA. Suppression of centromere dynamics by Taxol in living osteosarcoma cells. Cancer Res 2003;63: 2794-801. (Pubitemid 36667150)
34. Jordan MA, Thrower D, Wilson L. Effects of vinblastine, podophyllotoxin and nocodazole on mitotic spindles. Implications for the role of microtubule dynamics in mitosis. J Cell Sci 1992;102:401-16.
35. Jordan MA, Toso RJ, Thrower D, Wilson L. Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Proc Natl Acad Sci U S A 1993;90:9552-6. (Pubitemid 23315823)
36. Spankuch-Schmitt B, Bereiter-Hahn J, Kaufmann M, Strebhardt K. Effect of RNA silencing of polo-like kinase-1 (PLK1) on apoptosis and spindle formation in human cancer cells. J Natl Cancer Inst 2002;94: 1863-77. (Pubitemid 36104631)
37. Okouneva T, Hill BT, Wilson L, Jordan MA. The effects of vinflunine, vinorelbine, and vinblastine on centromere dynamics. Mol Cancer Ther 2003;2:427-36.
38. Lansing TJ, McConnell RT, Duckett DR, Spehar GM, Knick VB, Hassler DF, et al. In vitro biological activity of a novel small-molecule inhibitor of polo-like kinase 1. Mol Cancer Ther 2007;6:450-9.
39. Seong YS, Min C, Li L, Yang JY, Kim SY, Cao X, et al. Characterization of a novel cyclin-dependent kinase 1 inhibitor, BMI-1026. Cancer research 2003;63: 7384-91. (Pubitemid 37413480)
40. Misra RN, Xiao H, Rawlins DB, Shan W, Kellar KA, Mulheron JG, et al. 1H-Pyrazolo[3,4-b]pyridine inhibitors of cyclin-dependent kinases: highly potent 2,6-Difluorophenacyl analogues. Bioorg Med Chem Lett 2003;13:2405-8.
41. Emanuel S, Rugg CA, Gruninger RH, Lin R, Fuentes-Pesquera A, Connolly PJ, et al. The in vitro and in vivo effects of JNJ-7706621: a dual inhibitor of cyclin-dependent kinases and aurora kinases. Cancer Res 2005;65:9038-46. (Pubitemid 41377396)
42. Huang S, Connolly PJ, Lin R, Emanuel S, Middleton SA. Synthesis and evaluation of N-acyl sulfonamides as potential prodrugs of cyclin-dependent kinase inhibitor JNJ-7706621. Bioorg Med Chem Lett 2006;16:3639-41. (Pubitemid 44164264)
43. Barvian M, Boschelli DH, Cossrow J, Dobrusin E, Fattaey A, Fritsch A, et al. Pyrido[2,3-d]pyrimidin-7-one inhibitors of cyclin-dependent kinases. J Med Chem 2000;43: 4606-16.